Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 111 entries
View as:

A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients

Phase: N/A Priority: Normal
NCT ID: NCT02204722 Org: User:
Start: 10/13/14 End: 01/09/18 Due: 01/09/19

Efficacy and Safety of DA-3002 in Children With Idiopathic Short Stature

Phase: N/A Priority: Normal
NCT ID: NCT01786902 Org: User:
Start: 02/29/12 End: 04/30/14 Due: 04/30/15

Study of DA-9801 to Treat Diabetic Neuropathic Pain

Phase: N/A Priority: Normal
NCT ID: NCT01813799 Org: User:
Start: 11/30/11 End: 07/31/13 Due: 07/31/14

A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01 Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg, and to Evaluate the Effect of Food on the Pharmacokinetics of DA-1229_01 in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02167061 Org: User:
Start: 07/31/14 End: 11/30/14 Due: 11/30/15

Bioequivalence Study Between "DA-5215 Tab" and "DA-5215-R Tab"

Phase: N/A Priority: Normal
NCT ID: NCT05376085 Org: User:
Start: 05/31/22 End: 07/31/22 Due: 07/31/23

Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application

Phase: N/A Priority: Normal
NCT ID: NCT02280603 Org: User:
Start: 01/31/14 End: 12/31/14 Due: 12/31/15

Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT04785326 Org: User:
Start: 04/28/21 End: 11/16/22 Due: 11/16/23

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of DA-2803 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04906109 Org: User:
Start: 07/12/21 End: 10/05/21 Due: 10/05/22

Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT05991401 Org: User:
Start: 08/18/23 End: 11/17/23 Due: 11/17/24

Phase 1 Clinical Trial to Evaluate the Safety, PK and PD of DA-5207 TDS in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT04479865 Org: User:
Start: 07/28/20 End: 04/30/21 Due: 04/30/22

Evaluation of Pharmacokinetic/Pharmacodynamic Properties and Safety of Leucostim® Compared to Neupogen® in Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02725086 Org: User:
Start: 02/29/16 End: 05/31/16 Due: 05/31/17

Pharmacokinetics and Safety Profiles After Administration of DA-5221_01 and Co-administration of 5221_01-R1 and DA-5221_01-R2 in Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT06616883 Org: User:
Start: 09/30/24 End: 11/18/24 Due: 11/18/25

Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects (DA-2811)

Phase: N/A Priority: Normal
NCT ID: NCT04938752 Org: User:
Start: 07/08/21 End: 08/20/21 Due: 08/20/22

The Food Effect on Pharmacokinetics of DA-8010 After a Single Administration of DA-8010 2.5 mg or 5 mg in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04686825 Org: User:
Start: 01/13/21 End: 03/11/21 Due: 03/11/22

A Study to Evaluate the Effects of Renal Function on Pharmacokinetics and Safety of DA-8010

Phase: N/A Priority: Normal
NCT ID: NCT05812417 Org: User:
Start: 05/02/23 End: 06/07/24 Due: 06/07/25

A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)

Phase: N/A Priority: Normal
NCT ID: NCT01751919 Org: User:
Start: 05/31/12 End: 08/31/12 Due: 08/31/13

Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fasting State

Phase: N/A Priority: Normal
NCT ID: NCT05098262 Org: User:
Start: 10/31/21 End: 01/03/22 Due: 01/03/23

Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT05992428 Org: User:
Start: 08/22/23 End: 12/05/23 Due: 12/05/24

A Study in Healthy Volunteers to Compare the Profiles of DA-3880 and EU Sourced ARANESP® (Amgen)

Phase: N/A Priority: Normal
NCT ID: NCT02241200 Org: User:
Start: 08/18/14 End: 11/29/14 Due: 11/29/15

Clinical Study to Evaluate Efficacy and Safety of DA-1229 in Patients With CAVD

Phase: N/A Priority: Normal
NCT ID: NCT04055883 Org: User:
Start: 08/26/19 End: 02/01/23 Due: 02/01/24

Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab.

Phase: N/A Priority: Normal
NCT ID: NCT04326166 Org: User:
Start: 03/25/20 End: 07/31/21 Due: 07/31/22

Phamacokinetics and Safety Profiles of DA-1229_01 5/1000mg in Healthy Subjects at Fasting State

Phase: N/A Priority: Normal
NCT ID: NCT05739903 Org: User:
Start: 03/25/23 End: 04/21/23 Due: 04/21/24

Phamacokinetics and Safety Profiles of DA-5210 10/1000mg in Healthy Subjects at Fasting State

Phase: N/A Priority: Normal
NCT ID: NCT05108571 Org: User:
Start: 10/28/21 End: 01/27/22 Due: 01/27/23

A Study to Investigate the Bioequivalence Test of DA-1229_01(A) at Fasting State

Phase: N/A Priority: Normal
NCT ID: NCT03939143 Org: User:
Start: 02/07/19 End: 04/04/19 Due: 04/04/20

To Evaluate Effect of Food of DA-5222 in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06993168 Org: User:
Start: 05/21/25 End: 07/31/25 Due: 07/31/26